FCM
RXST icon

Farallon Capital Management’s RxSight RXST Stock Holding History

Farallon Capital Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-175,000
Closed -$4.42M – 155
2025
Q1 		$4.42M Buy
+175,000
New +$5.2M 0.02% 82

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Farallon Capital Management's RXST Position: Q2 2025 in Review

Farallon Capital Management sold out of RxSight (RXST) in Q2 2025, closing a stake of 175,000 shares — an estimated $4.42M sold.

Farallon Capital Management first reported a position in RXST in Q1 2025 and held it in 1 quarter. The position peaked at $4.42M in Q1 2025. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

  • Farallon Capital Management reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
  • Farallon Capital Management sold 175,000 RxSight shares in Q2 2025, an estimated $4.42M.
  • Farallon Capital Management first reported a position in RxSight in Q1 2025 and held it in 1 quarter.
  • Farallon Capital Management's RxSight position peaked at $4.42M in Q1 2025.
  • 174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.